Literature DB >> 15082597

Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

R Mariani1, C Arosio, S Pelucchi, M Grisoli, A Piga, P Trombini, A Piperno.   

Abstract

We describe a novel missense mutation of ceruloplasmin in a patient with aceruloplasminaemia causing the replacement of a neutral amino acid (phenylalanine) with a polar one (serine) at position 198, probably leading to abnormal folding and secretion of the protein. The patient showed mild microcytic anaemia, mild hepatic iron overload, and marked brain iron overload. Six months of therapy with deferiprone was ineffective in removing iron from the tissues. Deferoxamine was more efficient in removing excess iron from the liver but aggravated the disease related anaemia. After more than one year of chelation treatment, the brain magnetic resonance imaging signal did not change. Overall, these findings indicate that treatment of iron overload in aceruloplasminaemia is a difficult challenge and that new iron chelators, more efficient in crossing the blood-brain barrier, are needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082597      PMCID: PMC1774045          DOI: 10.1136/gut.2003.030429

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Hepatic iron overload in aceruloplasminaemia.

Authors:  N E Hellman; M Schaefer; S Gehrke; P Stegen; W J Hoffman; J D Gitlin; W Stremmel
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation.

Authors:  H Miyajima; S Kono; Y Takahashi; M Sugimoto; M Sakamoto; N Sakai
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

3.  Role of ceruloplasmin in cellular iron uptake.

Authors:  C K Mukhopadhyay; Z K Attieh; P L Fox
Journal:  Science       Date:  1998-01-30       Impact factor: 47.728

4.  Biochemical analysis of a missense mutation in aceruloplasminemia.

Authors:  Nathan E Hellman; Satoshi Kono; Hiroaki Miyajima; Jonathan D Gitlin
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

5.  A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin.

Authors:  P L Lee; T Gelbart; C West; C Halloran; V Felitti; E Beutler
Journal:  Blood Cells Mol Dis       Date:  2001 Sep-Oct       Impact factor: 3.039

6.  Use of desferrioxamine in the treatment of aceruloplasminemia.

Authors:  H Miyajima; Y Takahashi; T Kamata; H Shimizu; N Sakai; J D Gitlin
Journal:  Ann Neurol       Date:  1997-03       Impact factor: 10.422

Review 7.  A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma.

Authors:  M Yonekawa; T Okabe; Y Asamoto; M Ohta
Journal:  Eur Neurol       Date:  1999       Impact factor: 1.710

8.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux.

Authors:  Z L Harris; A P Durley; T K Man; J D Gitlin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

9.  Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family.

Authors:  H Morita; S Ikeda; K Yamamoto; S Morita; K Yoshida; S Nomoto; M Kato; N Yanagisawa
Journal:  Ann Neurol       Date:  1995-05       Impact factor: 10.422

Review 10.  Iron deficiency and overload.

Authors:  Ernest Beutler; A Victor Hoffbrand; James D Cook
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2003
View more
  15 in total

1.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

2.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

3.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 4.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

5.  Inhibition of prostate cancer proliferation by Deferiprone.

Authors:  Rui V Simões; Suresh Veeraperumal; Inna S Serganova; Natalia Kruchevsky; Joseph Varshavsky; Ronald G Blasberg; Ellen Ackerstaff; Jason A Koutcher
Journal:  NMR Biomed       Date:  2017-03-08       Impact factor: 4.044

6.  Various copper and iron overload patterns in the livers of patients with Wilson disease and idiopathic copper toxicosis.

Authors:  Hisao Hayashi; Ai Hattori; Yasuaki Tatsumi; Kazuhiko Hayashi; Yoshiaki Katano; Jun Ueyama; Shinya Wakusawa; Motoyoshi Yano; Hidemi Goto
Journal:  Med Mol Morphol       Date:  2013-01-22       Impact factor: 2.309

7.  Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.

Authors:  Liangliang Zhao; Majda Hadziahmetovic; Chenguang Wang; Xueying Xu; Ying Song; H A Jinnah; Jolanta Wodzinska; Jared Iacovelli; Natalie Wolkow; Predrag Krajacic; Alyssa Cwanger Weissberger; John Connelly; Michael Spino; Michael K Lee; James Connor; Benoit Giasson; Z Leah Harris; Joshua L Dunaief
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

8.  Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Authors:  Armin Finkenstedt; Elisabeth Wolf; Elmar Höfner; Bethina Isasi Gasser; Sylvia Bösch; Rania Bakry; Marc Creus; Christian Kremser; Michael Schocke; Milan Theurl; Patrizia Moser; Melanie Schranz; Guenther Bonn; Werner Poewe; Wolfgang Vogel; Andreas R Janecke; Heinz Zoller
Journal:  J Hepatol       Date:  2010-08-04       Impact factor: 25.083

9.  Iron metabolism in thalassemia and sickle cell disease.

Authors:  Raffaella Mariani; Paola Trombini; Matteo Pozzi; Alberto Piperno
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-10-27       Impact factor: 2.576

10.  Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).

Authors:  Susanne A Schneider; Petr Dusek; John Hardy; Ana Westenberger; Joseph Jankovic; Kailash P Bhatia
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.